Regeneron Pharmaceuticals, Inc. REGN

NAS: REGN | ISIN: US75886F1075   11/09/2026
781,49 USD (-1,48%)
(-1,48%)   11/09/2026

10 september 2026 · SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN · Persbericht

10 september 2026 · Faruqi & Faruqi, LLP Urges Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors to Seek Counsel Before the September 14, 2026 Lead Plaintiff Deadline in the Securities Class Action · Persbericht

10 september 2026 · REGN MONDAY DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit · Persbericht

9 september 2026 · Levi & Korsinsky Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026 - REGN · Persbericht

1 september 2026 · INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit Before September 14, 2026 Deadline · Persbericht

28 augustus 2026 · Regeneron Pharmaceuticals, Inc. (REGN) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before September 14, 2026 Lead Plaintiff Deadline · Persbericht

27 augustus 2026 · REGN DEADLINE: SueWallSt Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline · Persbericht

27 augustus 2026 · Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit · Persbericht

24 augustus 2026 · Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP · Persbericht

20 augustus 2026 · Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit · Persbericht

20 augustus 2026 · REGN Stockholders Interested in Leading the Class Action Against Regeneron Pharmaceuticals, Inc. Should Contact Robbins LLP for Information About Recovering Their Losses · Persbericht

18 augustus 2026 · Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP · Persbericht

14 augustus 2026 · Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - Hagens Berman · Persbericht

12 augustus 2026 · Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP · Persbericht

10 augustus 2026 · Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP · Persbericht

6 augustus 2026 · SueWallSt Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026 - REGN · Persbericht

4 augustus 2026 · REGN Stock Drop: Regeneron Clinical Trials Lead to 9% Stock Drop and Securities Fraud Class Action for Investors · Persbericht

3 augustus 2026 · REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm · Persbericht

31 juli 2026 · Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure - HBSS · Persbericht

29 juli 2026 · REGN UPCOMING DEADLINE: Levi & Korsinsky Alerts Regeneron Pharmaceuticals, Inc. Stockholders of Securities Class Action - Contact the Firm · Persbericht

Mijn selecties